/CPRX
CPRX Stock - Catalyst Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$23.74+0.30%
+$0.07 (+0.30%) • Dec 19
81
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.71
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.93
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+39.0%upside
Target: $33.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CPRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$23.50 – $23.98
TARGET (TP)$33.00
STOP LOSS$21.84
RISK/REWARD1:4.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.68
52W High$26.58
52W Low$19.05
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $491.73M | $398.20M | $214.20M | $140.83M | $119.07M |
| Gross Profit | $422.89M | $346.24M | $179.81M | $118.95M | $102.03M |
| Gross Margin | 86.0% | 86.9% | 83.9% | 84.5% | 85.7% |
| Operating Income | $195.12M | $86.81M | $101.84M | $52.38M | $41.30M |
| Net Income | $163.89M | $71.41M | $83.08M | $39.48M | $74.98M |
| Net Margin | 33.3% | 17.9% | 38.8% | 28.0% | 63.0% |
| EPS | $1.38 | $0.67 | $0.80 | $0.38 | $0.72 |
Company Overview
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
80%
Hold / Neutral
1
20%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
4 Bullish1 Neutral/Bearish
Price Targets
$26
Average Target
↑ 11.3% Upside
Now
$16
Low
$26
Average
$35
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| February 4th 2025 | Robert W. Baird | Initiation | Outperform | $28 |
| November 18th 2024 | Stephens | Initiation | Overweight | $35 |
| March 14th 2024 | Citigroup | Initiation | Buy | $27 |
| March 7th 2024 | BofA Securities | Initiation | Buy | $23 |
| December 21st 2023 | Oppenheimer | Initiation | Outperform | $30 |
| August 24th 2022 | ROTH Capital | Downgrade | Neutral | $15.5← $10 |
Earnings History & Surprises
CPRXBeat Rate
72%
Last 18 quarters
Avg Surprise
+19.4%
EPS vs Estimate
Beats / Misses
13/3
2 met exactly
Latest EPS
$0.68
Q4 2025
EPS Surprise History
Q1 24
+10.4%
$0.53vs$0.48
Q2 24
+11.8%
$0.38vs$0.34
Q3 24
+33.3%
$0.56vs$0.42
Q4 24
+16.3%
$0.57vs$0.49
Q1 25
+118.7%
$0.70vs$0.32
Q2 25
+28.3%
$0.68vs$0.53
Q3 25
+17.2%
$0.68vs$0.58
Q4 25
+33.3%
$0.68vs$0.51
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $0.39 | — | — | — |
Q4 2025 | Nov 5, 2025 | $0.51 | $0.68 | +33.3% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $0.58 | $0.68 | +17.2% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $0.53 | $0.68 | +28.3% | ✓ BEAT |
Q1 2025 | Feb 26, 2025 | $0.32 | $0.70 | +118.7% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $0.49 | $0.57 | +16.3% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $0.42 | $0.56 | +33.3% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $0.34 | $0.38 | +11.8% | ✓ BEAT |
Q1 2024 | Feb 28, 2024 | $0.48 | $0.53 | +10.4% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-0.24 | $-0.24 | 0.0% | = MET |
Q3 2023 | Aug 9, 2023 | $0.25 | $0.33 | +32.0% | ✓ BEAT |
Q2 2023 | May 10, 2023 | $0.32 | $0.26 | -18.8% | ✗ MISS |
Q1 2023 | Mar 15, 2023 | $0.21 | $0.22 | +4.8% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $0.19 | $0.20 | +5.3% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $0.17 | $0.20 | +17.6% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $0.14 | $0.12 | -14.3% | ✗ MISS |
Q1 2022 | Mar 16, 2022 | $0.12 | $0.09 | -25.0% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $0.10 | $0.10 | 0.0% | = MET |
Q3 2021 | Aug 9, 2021 | $0.09 | $0.16 | +77.8% | ✓ BEAT |
Latest News
Citigroup Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $33
📈 PositiveBenzinga•Nov 7, 2025, 08:53 PM•Also:
CPRX stock has given up its prior gain. Catalyst Pharmaceuticals shares were trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.
➖ NeutralBenzinga•Nov 6, 2025, 03:03 PM
Catalyst Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.
📈 PositiveBenzinga•Nov 6, 2025, 11:25 AM
Catalyst Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.
📈 PositiveBenzinga•Nov 5, 2025, 10:10 PM
Catalyst Pharmaceuticals Raises FY2025 Sales Guidance from $545.000M-$565.000M to $565.000M-$585.000M vs $562.053M Est
📈 PositiveBenzinga•Nov 5, 2025, 09:18 PM
Catalyst Pharmaceuticals Q3 Adj. EPS $0.68 Beats $0.33 Estimate, Sales $148.392M Beat $136.802M Estimate
📈 PositiveBenzinga•Nov 5, 2025, 09:18 PM
Catalyst Pharmaceuticals Board Authorizes $200M Share Repurchase Program
📈 PositiveBenzinga•Oct 1, 2025, 12:04 PM
Catalyst Pharmaceuticals Reaches Settlement With Lupin To Delay Generic FIRDAPSE Launch Until 2035
📈 PositiveBenzinga•Aug 25, 2025, 12:06 PM
Frequently Asked Questions about CPRX
What is CPRX's current stock price?
Catalyst Pharmaceuticals, Inc. (CPRX) is currently trading at $23.74 per share. The stock has moved +0.30% today.
What is the analyst price target for CPRX?
The average analyst price target for CPRX is $33.00, based on 1 analyst.
What sector is Catalyst Pharmaceuticals, Inc. in?
Catalyst Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CPRX's market cap?
Catalyst Pharmaceuticals, Inc. has a market capitalization of $2.92 billion, making it a mid-cap company.
Does CPRX pay dividends?
No, Catalyst Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADPT
Adaptive Biotechnologies Corporation
$17.00
Mkt Cap: $2.6B
AGIO
Agios Pharmaceuticals, Inc.
$24.46
Mkt Cap: $1.4B
APLS
Apellis Pharmaceuticals, Inc.
$24.65
Mkt Cap: $3.1B
BEAM
Beam Therapeutics Inc.
$26.57
Mkt Cap: $2.7B
CDTX
Cidara Therapeutics, Inc.
$220.80
Mkt Cap: $5.6B
IDYA
IDEAYA Biosciences, Inc.
$33.55
Mkt Cap: $2.9B
KNSA
Kiniksa Pharmaceuticals, Ltd.
$43.19
Mkt Cap: $3.2B
MLYS
Mineralys Therapeutics, Inc.
$36.83
Mkt Cap: $2.4B
RXRX
Recursion Pharmaceuticals, Inc.
$4.26
Mkt Cap: $1.7B
SRRK
Scholar Rock Holding Corporation
$43.90
Mkt Cap: $4.5B
Explore stocks similar to CPRX for comparison